AU2020351159A1 - Protein tag to induce ligand dependent degradation of protein/protein-fusions - Google Patents

Protein tag to induce ligand dependent degradation of protein/protein-fusions Download PDF

Info

Publication number
AU2020351159A1
AU2020351159A1 AU2020351159A AU2020351159A AU2020351159A1 AU 2020351159 A1 AU2020351159 A1 AU 2020351159A1 AU 2020351159 A AU2020351159 A AU 2020351159A AU 2020351159 A AU2020351159 A AU 2020351159A AU 2020351159 A1 AU2020351159 A1 AU 2020351159A1
Authority
AU
Australia
Prior art keywords
protein
dcaf15
cell
degron tag
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020351159A
Other languages
English (en)
Inventor
Shourya Sonkar Roy BURMAN
Tyler FAUST
Eric S. FISCHER
Radoslaw P. NOWAK
Hojong YOON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of AU2020351159A1 publication Critical patent/AU2020351159A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/85—Fusion polypeptide containing an RNA binding domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020351159A 2019-09-18 2020-09-17 Protein tag to induce ligand dependent degradation of protein/protein-fusions Abandoned AU2020351159A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962902275P 2019-09-18 2019-09-18
US62/902,275 2019-09-18
PCT/US2020/051156 WO2021055530A1 (en) 2019-09-18 2020-09-17 Protein tag to induce ligand dependent degradation of protein/protein-fusions

Publications (1)

Publication Number Publication Date
AU2020351159A1 true AU2020351159A1 (en) 2022-02-24

Family

ID=74883712

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020351159A Abandoned AU2020351159A1 (en) 2019-09-18 2020-09-17 Protein tag to induce ligand dependent degradation of protein/protein-fusions

Country Status (6)

Country Link
US (1) US12428459B2 (enExample)
EP (1) EP4031163A4 (enExample)
JP (1) JP2022549085A (enExample)
AU (1) AU2020351159A1 (enExample)
CA (1) CA3150308A1 (enExample)
WO (1) WO2021055530A1 (enExample)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2922554T3 (pl) * 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US10550379B2 (en) 2015-06-29 2020-02-04 The Board Of Trustees Of The Leland Stanford Junior University Degron fusion constructs and methods for controlling protein production
CN109715808A (zh) * 2016-04-15 2019-05-03 诺华股份有限公司 用于选择性蛋白质表达的组合物和方法
US11807606B2 (en) * 2018-01-25 2023-11-07 Dana-Farber Cancer Institute, Inc. Sulfonamide derivatives for protein degradation

Also Published As

Publication number Publication date
EP4031163A1 (en) 2022-07-27
EP4031163A4 (en) 2023-09-13
US12428459B2 (en) 2025-09-30
JP2022549085A (ja) 2022-11-24
WO2021055530A1 (en) 2021-03-25
US20220402981A1 (en) 2022-12-22
CA3150308A1 (en) 2021-03-25

Similar Documents

Publication Publication Date Title
Roggenkamp et al. HN1L/JPT2: A signaling protein that connects NAADP generation to Ca2+ microdomain formation
Dooley et al. A versatile platform for generating engineered extracellular vesicles with defined therapeutic properties
US10683360B2 (en) Targeted protein degradation
KR20250019668A (ko) 순환 인자를 조절하기 위한 조성물 및 방법
US20180112219A1 (en) Compositions comprising talens and methods of treating hiv
BR112020026386A2 (pt) Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
Mohamed et al. The CRL4DCAF1 cullin‐RING ubiquitin ligase is activated following a switch in oligomerization state
US20220098251A1 (en) Peptide tags for ligand induced degradation of fusion proteins
US11655283B2 (en) HLA-G transcripts and isoforms and their uses
Malhotra et al. Defective cell adhesion function of solute transporter, SLC4A11, in endothelial corneal dystrophies
JP2022519275A (ja) エクソソーム操作のための膜タンパク質足場
AU2020351159A1 (en) Protein tag to induce ligand dependent degradation of protein/protein-fusions
US20160200804A1 (en) Compositions and methods for treating anaplastic thyroid cancer
EP2780356B1 (fr) Peptides inhibiteurs de l'interaction entre asf1 et les histones, et leurs utilisations
Sharma et al. An early, novel arginine methylation of KCa3. 1 attenuates subsequent T cell exhaustion
Doron-Mandel et al. GAR-driven subcellular localization of the growth controlling RNA binding protein nucleolin
US20240382590A1 (en) Novel tumor-specific antigens for cancer stem cells and uses thereof
Green et al. An early, novel arginine methylation of KCa3. 1 attenuates subsequent T cell exhaustion.
Semberova et al. CMTM6 suppresses cell-surface expression of death receptor FAS in mice but not in humans
Kellner et al. The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells. Cells 2024, 13, 1563
WO2026074493A1 (en) Materials, methods, and systems for enhanced protease targeting
AU2023378372A1 (en) Novel drug-inducible degradation tags
Jackson Conserved Non-Pocket Interactions Drive The Diversity of Peptide Presentation By Mhc Class I Molecules
WO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤
WO2016018454A2 (en) Compositions and methods employing bcl2 and bcl2 family members

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application